Minimally Invasive Fetoscopic Regenerative Repair of Spina Bifida - A Pilot Study

This is an interventional treatment trial for Spina Bifida Read More

Inclusion Criteria

• Pregnant women - maternal age 18 years or older
• Gestational age at the time of the procedure between 19 0/7 weeks and 25 6/7 weeks
• Singleton pregnancy.

• MMC diagnosis with the upper boundary located between Thoracic 1 (T1) and Sacral

  1 (S1).

• Evidence of hindbrain herniation (confirmed on MRI to have an Arnold-Chiari type II malformation).
• Absence of chromosomal abnormalities and associated anomalies.
• Normal karyotype and/or normal chromosomal microarray (CMA) by invasive testing (amniocentesis or CVS). If there is a balanced translocation with normal CMA with no other anomalies the candidate can be included.
• Family has considered and declined the option of termination of the pregnancy at less than 24 weeks.
• Family meets psychosocial criteria (sufficient social support, ability to understand requirements for this study).
• Pregnant subject capable of consenting for their own participation in this study.
• Willingness to undergo an open MMC repair, if necessary
• Parental/guardian permission (informed consent) for follow up of child after birth.

Exclusion Criteria:

• Exclusion Criteria

  • Fetal anomaly unrelated to MMC.
  • Multiple gestation
  • Declined invasive testing for karyotype (amniocentesis or CVS)
  • Severe kyphosis (defined as curvature of the spina (vertebras) higher than 30o degree measured by ultrasonography or magnetic resonance imaging).
  • Increased risk for preterm labor including short cervical length (<2.0 cm), history of incompetent cervix with or without cerclage, and previous preterm birth.
  • Placental abnormalities (previa, abruption, accreta) known at time of enrollment.
  • A body-mass index ≥40 at first prenatal visit.
  • Contraindications to surgery including previous hysterotomy (whether from a previous classical cesarean, uterine anomaly such as an arcuate or bicornuate uterus, major myomectomy resection, or previous fetal surgery) in active uterine segment.
  • Technical limitations precluding fetoscopic surgery, such as uterine fibroids, fetal membrane separation, uterine anomalies incompatible with fetoscopy.
  • Amniotic Fluid Index (AFI) < 6 cm if deemed to be due to fetal anomaly, poor placental perfusion or function, or membrane rupture. Low amniotic fluid volume that responds to maternal hydration is not an exclusion.
  • Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy.
  • Maternal HIV, Hepatitis-B, Hepatitis-C status positive because of the increased risk of transmission to the fetus during maternal-fetal surgery. If the patients HIV or Hepatitis status is unknown, the patient must be tested and found to have negative results before enrollment.
  • Maternal medical condition that is a contraindication to surgery or anesthesia.
  • A score of ≥ 29 on the Beck Depression Inventory (BDI) at screening
  • Maternal hypersensitivity to collagen
  • Patient does not have a support person (i.e. Spouse, partner, mother) available to support the patient for the duration of the pregnancy.
  • Inability to comply with the travel and follow-up requirements of the trial.
  • Participation in another intervention study that influences maternal and fetal morbidity and mortality or participation in this trial in a previous pregnancy.